

Company re-branding

9 August 2019: Phylogica Limited ('The Company') wishes to announce that it has re-branded itself as 'PYC Therapeutics'.

The Company has registered a new business name with the Australian Securities and Investments Commission and has also made a trademark application to IP Australia in support of the new name.

The primary driver of the re-branding of the Company is to explicitly acknowledge the transition that the Company has undertaken from drug discovery to drug development. There has been a substantial amount of change that has occurred within the organisation over the past 18 months in order to realise this transition. These supporting changes included a new Executive, Board, and Scientific Advisory Board as well as clear definition of the pathway to the clinical development of the Company's technology.

The Company recently demonstrated the progress that it has made on the back of these changes in announcing successful results across the two critical outcomes that measure the effectiveness of a therapeutic at the pre-clinical development stage:

- i) A substantial competitive advantage in animal models (see ASX announcement of 23 July 2019); and
- ii) Proven delivery in human cells (see ASX announcement of 6 August 2019).

The Company now has a clear focus on the commercialisation of its technology starting with the advancement of treatments for inherited retinal diseases into clinical development. This separates it from its historical approach to discovery efforts related to its proprietary drug libraries. The Company's purpose is to use the power of its delivery technology to create a new class of therapeutics in areas of significant unmet medical need. The name PYC Therapeutics better reflects that purpose.

The re-branding of the Company will precede an investor relations and business development effort focused on the progress the Company has made and the near-term milestones that will add shareholder value. The re-branding will be supported by a comprehensive overhaul of the Company's website to reflect the changes described above.

Shareholder approval is required for the Company to re-name itself 'PYC Therapeutics Limited'. The use of a Business Name (Trading name) is an interim measure and it is anticipated that shareholder approval will be sought for renaming at the Company's Annual General Meeting.

ENDS

For further information, please contact:

INVESTORS
Rohan Hockings
CEO
rohanhockings@pyctx.com

About PYC Therapeutics

Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6319 1000 | Fax: +61 8 6319 1777

pyctx.com

Phylogica Limited trading as PYC Therapeutics

ACN 098 391 961